Cancer statistics for African Americans, 2019

CA Cancer Journal for Clinicians

Volumn 69, Issue 3, 2019, Pages 211-233

  DeSantis, Carol E ^a   Miller, Kimberly D ^a   Goding Sauer, Ann ^a   Jemal, Ahmedin ^a   Siegel, Rebecca L ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

blacks; cancer statistics; incidence; mortality

Indexed keywords

ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER STATISTICS; CANCER SURVIVAL; CAUCASIAN; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LUNG CANCER; MALE; MALIGNANT NEOPLASM; MORTALITY RATE; PANCREAS CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; UTERUS CANCER; EPIDEMIOLOGY; ETHNOLOGY; HEALTH CARE DISPARITY; HEALTH DISPARITY; INCIDENCE; MORTALITY; NEOPLASM; PREVALENCE; UNITED STATES;

AFRICAN AMERICANS; FEMALE; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HUMANS; INCIDENCE; MALE; NEOPLASMS; PREVALENCE; RISK FACTORS; SEER PROGRAM; UNITED STATES;

EID: 85061579587     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21555     Document Type: Article

References (122)

1. Fontenot K, Semega J, Kollar M; US Census Bureau. Income and Poverty in the United States: 2017. Current Population Reports P60-263. Washington, DC: US Government Printing Office; 2018.
2. US Census Bureau. Educational Attainment in the United States: 2017. Table 1. Educational Attainment of the Population 18 Years and Over, by Age, Sex, Race, and Hispanic Origin: 2017. Suitland, MD: US Census Bureau; 2017. census.gov/data/tables/2017/demo/education-attainment/cps-detailed-tables.html. Accessed November 27, 2018.
3. Pan HY, Walker GV, Grant SR, et al. Insurance status and racial disparities in cancer-specific mortality in the United States: a population-based analysis. Cancer Epidemiol Biomarkers Prev. 2017;26:869-875.
4. Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008;58:9-31.
5. Niu X, Roche LM, Pawlish KS, Henry KA. Cancer survival disparities by health insurance status. Cancer Med. 2013;2:403-411.
6. Berchick E, Hood E, Barnett J. Health Insurance Coverage in the United States: 2017. Current Population Reports P60-264. Washington, DC: US Government Printing Office; 2018.
7. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30.
8. Soni A, Sabik LM, Simon K, Sommers BD. Changes in insurance coverage among cancer patients under the Affordable Care Act. JAMA Oncol. 2018;4:122-124.
9. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Research Data with Delay-Adjustment, Malignant Only, Nov 2017 Sub (1975-2015) Linked To County Attributes-Total US, 1969-2013 Counties. Bethesda, MD: National Cancer Institute, Department of Cancer Control and Population Sciences, Surveillance Research Program; 2018.
10. Noone AM, Howlader N, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2015. Bethesda, MD: National Cancer Institute; 2018.
11. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data-CiNA Analytic File, 1995-2015, for NHIA v2 Origin, Custom File With County, American Cancer Society (ACS) Facts and Figures Projection Project. Springfield, IL: North American Association of Central Cancer Registries; 2018.
12. Copeland G, Green D, Firth R, et al, eds. Cancer in North America: 2011-2015. Vol 1. Combined Cancer Incidence for the United States, Canada and North America. Springfield, IL: North American Association of Central Cancer Registries; 2018.
13. Copeland G, Green D, Firth R, et al, eds. Cancer in North America: 2011-2015. Vol 2. Registry-Specific Cancer Incidence for the United States and Canada. Springfield, IL: North American Association of Central Cancer Registries; 2018.
14. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality-All COD, Total US (1969-2016) Linked To County Attributes-Total US, 1969-2016 Counties. Bethesda, MD: National Cancer Institute, Department of Cancer Control and Population Sciences, Surveillance Research Program; 2018 (underlying mortality data provided by the National Center for Health Statistics).
15. Fritz A, Percy C, Jack A, et al. eds. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
16. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th Revision. Volumes I-III. Geneva, Switzerland: World Health Organization; 2011.
17. Statistical Research and Applications Branch, National Cancer Institute. DevCan: Probability of Developing or Dying of Cancer Software. Version 6.7.6. Bethesda, MD: Surveillance Research Program, Statistical Methodology and Applications, National Cancer Institute; 2018.
18. Surveillance Research Program, National Cancer Institute. SEER*Stat Software. Version 8.3.5. Bethesda, MD: National Cancer Institute; 2018.
19. Statistical Research and Applications Branch, National Cancer Institute. Joinpoint Regression Program, Version 4.6.0.0. April, 2018; Bethesda, MD: Statistical Research and Applications Branch, National Cancer Institute; 2018.
20. Pickle LW, Hao Y, Jemal A, et al. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin. 2007;57:30-42.
21. Zhu L, Pickle LW, Ghosh K, et al. Predicting US- and state-level cancer counts for the current calendar year: part II: evaluation of spatiotemporal projection methods for incidence. Cancer 2012;118:1100-1109.
22. Chen HS, Portier K, Ghosh K, et al. Predicting US- and state-level cancer counts for the current calendar year: part I: evaluation of temporal projection methods for mortality. Cancer 2012;118:1091-1099.
23. National Center for Health Statistics. National Health Interview Survey, 2017. Public-use data file and documentation. Hyattsville, MD: National Center for Health Statistics; 2018. cdc.gov/nchs.nhis.htm. Accessed July 9, 2018.
24. National Center for Health Statistics. National Health and Nutrition Examination Survey, 2015-2016. Public-use data file and documentation. Hyattsville, MD: National Center for Health Statistics; 2018. cdc.gov/nchs/nhanes/index.htm. Accessed November 4, 2018.
25. Siegel RL, Devesa SS, Cokkinides V, Ma J, Jemal A. State-level uterine corpus cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008. Cancer Epidemiol Biomarkers Prev. 2013;22:25-31.
26. Jamison PM, Noone AM, Ries LA, Lee NC, Edwards BK. Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev. 2013;22:233-241.
27. Singh GK, Jemal A. Socioeconomic and racial/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950-2014: over six decades of changing patterns and widening inequalities [serial online]. J Environ Public Health. 2017;2017:2819372.
28. Simard EP, Fedewa S, Ma J, Siegel R, Jemal A. Widening socioeconomic disparities in cervical cancer mortality among women in 26 states, 1993-2007. Cancer 2012;118:5110-5116.
29. Jemal A, Center MM, Ward E. The convergence of lung cancer rates between blacks and whites under the age of 40, United States. Cancer Epidemiol Biomarkers Prev. 2009;18:3349-3352.
30. Simard EP, Naishadham D, Saslow D, Jemal A. Age-specific trends in black-white disparities in cervical cancer incidence in the United States: 1975-2009. Gynecol Oncol. 2012;127:611-615.
31. Zeng C, Wen W, Morgans AK, Pao W, Shu XO, Zheng W. Disparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program in the United States, 1990 to 2010. JAMA Oncol. 2015;1:88-96.
32. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA 2002;287:2106-2113.
33. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94:334-357.
34. Smedley BD, Stith AY, Nelson AR, eds. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. Washington, DC: The National Academies Press; 2002.
35. Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. Racial and ethnic disparities in cancer survival: the contribution of tumor, sociodemographic, institutional, and neighborhood characteristics. J Clin Oncol. 2018;36:25-33.
36. Kish JK, Yu M, Percy-Laurry A, Altekruse SF. Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) registries. J Natl Cancer Inst Monogr. 2014;2014:236-243.
37. Du XL, Lin CC, Johnson NJ, Altekruse S. Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival: findings from the National Longitudinal Mortality Study, 1979-2003. Cancer 2011;117:3242-3251.
38. Lam C, Cronin K, Ballard R, Mariotto A. Differences in cancer survival among white and black cancer patients by presence of diabetes mellitus: estimations based on SEER-Medicare-linked data resource. Cancer Med. 2018;7:3434-3444.
39. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 2005;294:1765-1772.
40. Newman LA, Kaljee LM. Health disparities and triple-negative breast cancer in African American women: a review. JAMA Surg. 2017;152:485-493.
41. Daly B, Olopade OI. A perfect storm: how tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin. 2015;65:221-238.
42. McGinley KF, Tay KJ, Moul JW. Prostate cancer in men of African origin. Nature Rev Urol. 2016;13:99-107.
43. Center for Information and Study on Clinical Research Participation (CISCRP). Proportion of study volunteers by race and ethnicity in clinical research studies, 2012 [serial online]. J Natl Cancer Inst. 2017;109:djx077.
44. Chen MSJr, Lara PN, Dang JH, Paterniti DA, Kelly K. Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials. Cancer 2014;120(suppl 7):1091-1096.
45. Wallace TA, Martin DN, Ambs S. Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis 2011;32:1107-1121.
46. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67:439-448.
47. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66:31-42.
48. DeSantis CE, JemalA. Re: black-white breast cancer incidence trends: effects of ethnicity [serial online]. J Natl Cancer Inst. 2018;110;djy162.
49. Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH. Proportion of US trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev. 2018;27:1214-1222.
50. Jemal A, Robbins AS, Lin CC, et al. Factors that contributed to black-white disparities in survival among nonelderly women with breast cancer between 2004 and 2013. J Clin Oncol. 2018;36:14-24.
51. Tao L, Gomez SL, Keegan TH, Kurian AW, Clarke CA. Breast cancer mortality in African-American and non-Hispanic white women by molecular subtype and stage at diagnosis: a population-based study. Cancer Epidemiol Biomarkers Prev. 2015;24:1039-1045.
52. Green AK, Aviki EM, Matsoukas K, Patil S, Korenstein D, Blinder V. Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2018;172:247-263.
53. Sighoko D, Murphy AM, Irizarry B, Rauscher G, Ferrans C, Ansell D. Changes in the racial disparity in breast cancer mortality in the ten US cities with the largest African American populations from 1999 to 2013: the reduction in breast cancer mortality disparity in Chicago. Cancer Causes Control. 2017;28:563-568.
54. Hunt BR, Hurlbert MS. Black:white disparities in breast cancer mortality in the 50 largest cities in the United States, 2005-2014. Cancer Epidemiol. 2016;45:169-173.
55. Rust G, Zhang S, Malhotra K, et al. Paths to health equity: local area variation in progress toward eliminating breast cancer mortality disparities, 1990-2009. Cancer 2015;121:2765-2774.
56. Moore JX, Royston KJ, Langston ME, et al. Mapping hot spots of breast cancer mortality in the United States: place matters for Blacks and Hispanics. Cancer Causes Control. 2018;29:739-750.
57. Allgood KL, Rauscher GH, Whitman S, Vasquez-Jones G, Shah AM. Validating self-reported mammography use in vulnerable communities: findings and recommendations. Cancer Epidemiol Biomarkers Prev. 2014;23:1649-1658.
58. Cronin KA, Miglioretti DL, Krapcho M, et al. Bias associated with self-report of prior screening mammography. Cancer Epidemiol Biomarkers Prev. 2009;18:1699-1705.
59. Rauscher GH, Johnson TP, Cho YI, Walk JA. Accuracy of self-reported cancer-screening histories: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008;17:748-757.
60. Molina Y, Silva A, Rauscher GH. Racial/ethnic disparities in time to a breast cancer diagnosis: the mediating effects of health care facility factors. Med Care. 2015;53:872-878.
61. George P, Chandwani S, Gabel M, et al. Diagnosis and surgical delays in African American and white women with early-stage breast cancer. J Womens Health (Larchmt). 2015;24:209-217.
62. Rauscher GH, Allgood KL, Whitman S, Conant E. Disparities in screening mammography services by race/ethnicity and health insurance. J Womens Health (Larchmt). 2012;21:154-160.
63. Warnecke RB, Campbell RT, Vijayasiri G, Barrett RE, Rauscher GH. A Multilevel examination of health disparity: the role of policy implementation in neighborhood context, in patient resources, and in healthcare facilities on later stage of breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev. 2019;28:59-66.
64. Doubeni CA, Major JM, Laiyemo AO, et al. Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J Natl Cancer Inst. 2012;104:1353-1362.
65. Fedewa SA, Flanders WD, Ward KC, et al. Racial and ethnic disparities in interval colorectal cancer incidence: a population-based cohort study. Ann Intern Med. 2017;166:857-866.
66. Irby K, Anderson WF, Henson DE, Devesa SS. Emerging and widening colorectal carcinoma disparities between blacks and whites in the United States (1975-2002). Cancer Epidemiol Biomarkers Prev. 2006;15:792-797.
67. Sineshaw HM, Ng K, Flanders WD, Brawley OW, Jemal A. Factors that contribute to differences in survival of black vs white patients with colorectal cancer. Gastroenterology 2018;154:906-915.e907.
68. Lai Y, Wang C, Civan JM, et al. Effects of cancer stage and treatment differences on racial disparities in survival from colon cancer: a United States population-based study. Gastroenterology 2016;150:1135-1146.
69. Silber JH, Rosenbaum PR, Ross RN, et al. Racial disparities in colon cancer survival: a matched cohort study. Ann Intern Med. 2014;161:845-854.
70. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002;20:1192-1202.
71. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005;294:2703-2711.
72. Thornton JG, Morris AM, Thornton JD, Flowers CR, McCashland TM. Racial variation in colorectal polyp and tumor location. J Natl Med Assoc. 2007;99:723-728.
73. Check DK, Albers KB, Uppal KM, et al. Examining the role of access to care: racial/ethnic differences in receipt of resection for early-stage non-small cell lung cancer among integrated system members and non-members. Lung Cancer 2018;125:51-56.
74. Lathan CS. Lung cancer care: the impact of facilities and area measures. Transl Lung Cancer Res. 2015;4:385-391.
75. Coughlin SS, Matthews-Juarez P, Juarez PD, Melton CE, King M. Opportunities to address lung cancer disparities among African Americans. Cancer Med. 2014;3:1467-1476.
76. Soneji S, Tanner NT, Silvestri GA, Lathan CS, Black W. Racial and ethnic disparities in early-stage lung cancer survival. Chest 2017;152:587-597.
77. Williams CD, Salama JK, Moghanaki D, Karas TZ, Kelley MJ. Impact of race on treatment and survival among US veterans with early-stage lung cancer. J Thorac Oncol. 2016;11:1672-1681.
78. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.
79. Smith CJ, Ambs S, Landgren O. Biological determinants of health disparities in multiple myeloma [serial online]. Blood Cancer J. 2018;8:85.
80. Landgren O, Graubard BI, Kumar S, et al. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey [serial online]. Blood Cancer J. 2017;7:e618.
81. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer—viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794-798.
82. Sonderman JS, Bethea TN, Kitahara CM, et al. Multiple myeloma mortality in relation to obesity among African Americans [serial online]. J Natl Cancer Inst. 2016;108:djw120.
83. Schinasi LH, Brown EE, Camp NJ, et al. Multiple myeloma and family history of lymphohaematopoietic cancers: results from the International Multiple Myeloma Consortium. Br J Haemotol. 2016;175:87-101.
84. Greenberg AJ, Rajkumar SV, Vachon CM. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood 2012;119:5359-5366.
85. Kazandjian D, Landgren O. A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol. 2016;43:682-689.
86. Negoita S, Feuer EJ, Mariotto A, et al. Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics. Cancer 2018;124:2801-2814.
87. Kicinski M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis [serial online]. PLoS One 2011;6:e27130.
88. Nemesure B, Wu SY, Hennis A, Leske MC. Family history of prostate cancer in a black population. J Immigr Minor Health. 2013;15:1107-1112.
89. World Cancer Research Fund International/American Institute for Cancer Research. Continuous Update Project Expert Report 2018: Diet, Nutrition, Physical Activity and Prostate Cancer. 2018. London, UK: World Cancer Fund International; 2018. dietandcancerreport.org. Accessed November 27, 2018.
90. Gansler T, Shah R, Wang Y, et al. Smoking and prostate cancer-specific mortality after diagnosis in a large prospective cohort. Cancer Epidemiol Biomarkers Prev. 2018;27:665-672.
91. Vidal AC, Freedland SJ. Obesity and prostate cancer: a focused update on active surveillance, race, and molecular subtyping. Eur Urol. 2017;72:78-83.
92. Barrington WE, Schenk JM, Etzioni R, et al. Difference in association of obesity with prostate cancer risk between US African American and non-Hispanic white men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncol. 2015;1:342-349.
93. Murphy AB, Akereyeni F, Nyame YA, et al. Smoking and prostate cancer in a multi-ethnic cohort. Prostate 2013;73:1518-1528.
94. Karakas C, Wang C, Deng F, Huang H, Wang D, Lee P. Molecular mechanisms involving prostate cancer racial disparity. Am J Clin Exp Urol. 2017;5:34-48.
95. Miller EA, Pinsky PF, Black A, Andriole GL, Pierre-Victor D. Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial. Prostate 2018;78:830-838.
96. Tsodikov A, Gulati R, de Carvalho TM, et al. Is prostate cancer different in black men? Answers from 3 natural history models. Cancer 2017;123:2312-2319.
97. Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2018;319:1914-1931.
98. Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 2017;123:592-599.
99. Lee DJ, Barocas DA, Zhao Z, et al. Contemporary prostate cancer radiation therapy in the United States: patterns of care and compliance with quality measures. Pract Rad Oncol. 2018;8:307-316.
100. Schmid M, Meyer CP, Reznor G, et al. Racial differences in the surgical care of Medicare beneficiaries with localized prostate cancer. JAMA Oncol. 2015;2:85-93.
101. Gupta S, Tao L, Murphy JD, et al. Race/ethnicity-, socioeconomic status-, and anatomic subsite-specific risks for gastric cancer. Gastroenterology 2019;156:59-62.e4.
102. Grad YH, Lipsitch M, Aiello AE. Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. Am J Epidemiol. 2012;175:54-59.
103. Nguyen T, Ramsey D, Graham D, et al. The prevalence of Helicobacter pylori remains high in African American and Hispanic veterans. Helicobacter. 2015;20:305-315.
104. Islami F, DeSantis CE, Jemal A. Incidence trends of esophageal and gastric cancer subtypes by race, ethnicity, and age in the United States, 1997-2014 [published online ahead of print June 11, 2018]. Clin Gastroenterol Hepatol. doi: 10.1016/j.cgh.2018.05.044.
105. Anderson WF, Rabkin CS, Turner N, Fraumeni JFJr, Rosenberg PS, Camargo MC. The changing face of noncardia gastric cancer incidence among US non-Hispanic whites. J Natl Cancer Inst. 2018;110:608-615.
106. Jim MA, Pinheiro PS, Carreira H, Espey DK, Wiggins CL, Weir HK. Stomach cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study. Cancer 2017;123(suppl 24):4994-5013.
107. White MC, Shoemaker ML, Benard VB. Cervical cancer screening and incidence by age: unmet needs near and after the stopping age for screening. Am J Prev Med. 2017;53:392-395.
108. Yoo W, Kim S, Huh WK, et al. Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States [serial online]. PLoS One 2017;12:e0172548.
109. Rositch AF, Nowak RG, Gravitt PE. Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer 2014;120:2032-2038.
110. Benard VB, Howe W, Royalty J, Helsel W, Kammerer W, Richardson LC. Timeliness of cervical cancer diagnosis and initiation of treatment in the National Breast and Cervical Cancer Early Detection Program. J Womens Health (Larchmt). 2012;21:776-782.
111. Horner MJ, Altekruse SF, Zou Z, Wideroff L, Katki HA, Stinchcomb DG. US geographic distribution of prevaccine era cervical cancer screening, incidence, stage, and mortality. Cancer Epidemiol Biomarkers Prev. 2011;20:591-599.
112. Churilla T, Egleston B, Dong Y, et al. Disparities in the management and outcome of cervical cancer in the United States according to health insurance status. Gynecol Oncol. 2016;141:516-523.
113. Markt SC, Tang T, Cronin AM, et al. Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival [serial online]. PLoS One 2018;13:e0193047.
114. Walker TY, Elam-Evans LD, Yankey D, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years—United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:909-917.
115. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination—updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2016;65:1405-1408.
116. Temkin SM, Kohn EC, Penberthy L, et al. Hysterectomy-corrected rates of endometrial cancer among women younger than age 50 in the United States. Cancer Causes Control. 2018;29:427-433.
117. Temkin SM, Minasian L, Noone AM. The end of the hysterectomy epidemic and endometrial cancer incidence: what are the unintended consequences of declining hysterectomy rates [serial online]?Front Oncol. 2016;6:89.
118. Felix AS, Brinton LA. Cancer progress and priorities: uterine cancer. Cancer Epidemiol Biomarkers Prev. 2018;27:985-994.
119. Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68:31-54.
120. Sud S, Holmes J, Eblan M, Chen R, Jones E. Clinical characteristics associated with racial disparities in endometrial cancer outcomes: a Surveillance, Epidemiology and End Results analysis. Gynecol Oncol. 2018;148:349-356.
121. Dubil EA, Tian C, Wang G, et al. Racial disparities in molecular subtypes of endometrial cancer. Gynecol Oncol. 2018;149:106-116.
122. Tarney CM, Tian C, Wang G, et al. Impact of age at diagnosis on racial disparities in endometrial cancer patients. Gynecol Oncol. 2018;149:12-21.